Tg Therapeutics (TGTX) EBIAT (2016 - 2025)
Tg Therapeutics has reported EBIAT over the past 10 years, most recently at $23.0 million for Q4 2025.
- Quarterly results put EBIAT at $23.0 million for Q4 2025, down 1.26% from a year ago — trailing twelve months through Dec 2025 was $447.2 million (up 1812.41% YoY), and the annual figure for FY2025 was $447.2 million, up 1812.41%.
- EBIAT for Q4 2025 was $23.0 million at Tg Therapeutics, down from $390.9 million in the prior quarter.
- Over the last five years, EBIAT for TGTX hit a ceiling of $390.9 million in Q3 2025 and a floor of -$93.3 million in Q4 2021.
- Median EBIAT over the past 5 years was -$25.1 million (2022), compared with a mean of -$4.4 million.
- Biggest five-year swings in EBIAT: tumbled 96.59% in 2024 and later surged 9974.61% in 2025.
- Tg Therapeutics' EBIAT stood at -$93.3 million in 2021, then increased by 15.93% to -$78.5 million in 2022, then soared by 81.63% to -$14.4 million in 2023, then skyrocketed by 261.84% to $23.3 million in 2024, then decreased by 1.26% to $23.0 million in 2025.
- The last three reported values for EBIAT were $23.0 million (Q4 2025), $390.9 million (Q3 2025), and $28.2 million (Q2 2025) per Business Quant data.